Personalized medicine in neuro-oncology

Written by Victor A Levin

The latest catch phrase in cancer medicine is ‘personalized medicine’ denoting the potential to devise and prescribe therapies based on molecular and genetic information quasi-unique to the patient and the patient’s tumor as well as therapies developed using cell line or rodent tumor model screens of drug candidates [1–8]. The molecular–genetic approach has the potential of being far more informative than the high-throughput cell line and/or rodent tumor model approach for a number of reasons. While some information can be obtained from glioblastoma cell lines and/or rodent tumor models, the main flaw of the cell line approach is the reality...

To view this content, please register now for access

It's completely free